Highlighting its continued interest in the development of antibody-drug conjugates (ADCs), Pfizer has partnered with start-up CytomX Therapeutics to use the company’s Probody™ platform to develop multiple Probody-drug conjugates in oncology. CytomX’s Probodies are masked antibodies that remain inert in healthy tissue but which are activated by proteases in the tumour microenvironment. News of the deal comes only weeks after Pfizer discontinued a Phase III study of its ADC inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin’s lymphoma.